OPEX® Corporation Announces Key Enhancements to Infinity® Automated Storage and Retrieval System
18.2.2025 10:00:00 CET | Business Wire | Press release
OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, is introducing significant enhancements to its Infinity® Automated Storage and Retrieval System (AS/RS). Enhanced features include a 15 percent increase in the system’s storage payload, along with new storage slotting capabilities.
The Infinity AS/RS, launched in 2022, combines unparalleled storage density, configurability and flexibility to meet the most pressing warehouse automation challenges in micro-fulfillment, omni-channel distribution, store replenishment and ecommerce. While the Infinity system was previously capable of supporting 70-pound (31.7 kilogram) payloads, the enhanced system can support 90-pound (40.8 kilogram) payloads. In addition to Infinity iBOT robots now supporting the increased payload, the racking structure, also known as the storage grid, has been updated to manage the increased weight, as well.
“The decision to increase Infinity’s payload has been driven by ongoing inquiries from our manufacturing customers,” explained Monty McVaugh, Head of Product at OPEX. “Many manufacturers want to store large, heavy, metal parts and sub-assemblies on their factory floor, such as alternators, fuel pumps, brake rotors, machining plates and more. The timing for our enhancements to the Infinity system is ideal, as the latest international building codes (IBC2021) outline loads that can be applied to structures, such as high bay storage racking, inside of industrial buildings. The adjustments OPEX has made to the Infinity storage racking comply with IBC2021 in both non-seismic and high-seismic regions.”
Manufacturers often leverage vertical lift modules to accommodate payload capabilities; however, these systems are typically not integrated into the warehouse management system. Accordingly, all transactions must be handled manually via spreadsheets and then imported into other inventory tracking systems. In addition, there is a limited selection of systems on the market that can handle 90 pounds or more per tote, making them capable of leveraging the full height of the warehouse and providing storage density in an efficient manner.
“Our enhanced Infinity AS/RS will also support smaller storage slot spacing,” added Zach Davis, Infinity Product Manager at OPEX. “Many manufacturers prefer to store hardware and fixturing tools on trays. Infinity will now support four-inch storage spacing when trays are utilized, nearly doubling the system’s eight-inch storage density.”
The Infinity goods-to-person (G2P) system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The system’s flexibility also accommodates varied workflows and layouts. Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput and labor utilization by eliminating wasted time.
“Our team at OPEX is always looking for new and better ways to meet evolving customer needs,” said McVaugh. “We’re excited to offer even greater functionality within our Infinity warehouse automation solutions.”
About OPEX
OPEX® Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has nearly 1,600 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and in the future. The year 2025 marks the company’s 50th anniversary under the multigenerational ownership and leadership of the Stevens family.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250218613197/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom